These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 21155482)
1. Injection of hope. Elliott M Nurs Stand; 2010 Nov 10-16; 25(10):23. PubMed ID: 21155482 [TBL] [Abstract][Full Text] [Related]
2. Denosumab (prolia) for postmenopausal osteoporosis. Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756 [No Abstract] [Full Text] [Related]
3. ... Fracture prevention. New osteoporosis drug improves patient adherence. Jones KW; Bushardt RL JAAPA; 2010 Dec; 23(12):56, 60. PubMed ID: 21229838 [No Abstract] [Full Text] [Related]
4. Denosumab, osteoporosis, and prevention of fractures. Blythe SL N Engl J Med; 2009 Nov; 361(22):2189-90; author reply 2190-1. PubMed ID: 19950410 [No Abstract] [Full Text] [Related]
5. Osteoporosis drug licensed for women with high fracture risk. Traynor K Am J Health Syst Pharm; 2010 Jul; 67(13):1046. PubMed ID: 20554585 [No Abstract] [Full Text] [Related]
7. Increasing options for the treatment of osteoporosis. Khosla S N Engl J Med; 2009 Aug; 361(8):818-20. PubMed ID: 19671654 [No Abstract] [Full Text] [Related]
8. Osteoporosis treatment options expand. Mayo Clin Health Lett; 2010 Nov; 28(11):4. PubMed ID: 21158019 [No Abstract] [Full Text] [Related]
9. Denosumab, osteoporosis, and prevention of fractures. Blackwood J N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950411 [No Abstract] [Full Text] [Related]
10. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C; N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655 [TBL] [Abstract][Full Text] [Related]
11. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Wensel TM; Iranikhah MM; Wilborn TW Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432 [TBL] [Abstract][Full Text] [Related]
14. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Hiligsmann M; Reginster JY Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422 [TBL] [Abstract][Full Text] [Related]
15. Denosumab: new horizons in the treatment of osteoporosis. Wilton JM Nurs Womens Health; 2011; 15(3):249-52. PubMed ID: 21672176 [No Abstract] [Full Text] [Related]
16. Choosing a treatment for patients at the time a fracture is presented. Tanner SB Curr Osteoporos Rep; 2011 Sep; 9(3):156-9. PubMed ID: 21655930 [TBL] [Abstract][Full Text] [Related]
18. The role and efficacy of denosumab in the treatment of osteoporosis: an update. Charopoulos I; Orme S; Giannoudis PV Expert Opin Drug Saf; 2011 Mar; 10(2):205-17. PubMed ID: 21208140 [TBL] [Abstract][Full Text] [Related]
19. Denosumab. Limited efficacy in fracture prevention, too many adverse effects. Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700 [TBL] [Abstract][Full Text] [Related]
20. Denosumab--a new option in the treatment of osteoporosis. Franek E Endokrynol Pol; 2011; 62(1):79-83. PubMed ID: 21365584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]